lexicon
pharmaceuticals
reports
third
quarter
financial
results
provides
clinical
update
woodlands
texas
globe
newswire
lexicon
pharmaceuticals
nasdaq
lxrx
today
reported
financial
results
three
months
ended
september
provided
update
key
milestones
third
quarter
streamlined
operations
prioritize
focus
advancement
promising
drug
candidate
potential
become
treatment
option
millions
people
living
neuropathic
pain
people
suffering
neuropathic
pain
experience
limited
success
available
therapies
enduring
substantial
side
effects
said
lonnel
coats
lexicon
president
chief
executive
officer
commenced
first
phase
study
diabetic
peripheral
neuropathic
pain
plan
commence
second
phase
study
neuralgia
shortly
results
studies
expected
end
next
third
quarter
highlights
commenced
patient
dosing
phase
randomized
clinical
study
treatment
diabetic
peripheral
neuropathic
pain
enrollment
expected
total
approximately
patients
clinical
sites
preparing
commence
additional
phase
study
neuralgia
later
year
realignment
debt
reduction
realignment
business
around
sotagliflozin
drug
discovery
development
programs
reduced
outstanding
debt
including
elimination
million
secured
term
loan
million
principal
amount
convertible
senior
notes
due
telotristat
ethyl
xermelo
net
sales
million
third
quarter
reflecting
sales
quarter
prior
completion
sale
xermelo
related
assets
tersera
therapeutics
llc
september
received
million
cash
closing
sale
eligible
receive
million
additional
milestone
payments
development
commercialization
xermelo
patients
biliary
tract
cancer
royalties
net
sales
xermelo
biliary
tract
cancer
sotagliflozin
announced
topline
data
four
phase
sotagliflozin
studies
type
diabetes
four
studies
meeting
primary
objectives
lowering
patients
type
diabetes
upcoming
milestones
initiation
phase
study
neuralgia
presentation
data
sotagliflozin
soloist
scored
phase
studies
american
heart
association
scientific
sessions
phase
study
results
diabetic
peripheral
neuropathic
pain
neuralgia
third
quarter
financial
highlights
revenues
revenues
three
months
ended
september
decreased
million
million
corresponding
period
three
months
ended
september
included
collaborative
revenues
million
termination
alliance
sanofi
recognition
remaining
amount
million
allocated
performance
obligations
initial
agreement
sanofi
net
product
revenues
three
months
ended
september
consisted
million
net
sales
xermelo
cost
sales
cost
sales
related
sales
xermelo
three
months
ended
september
million
research
development
r
expenses
research
development
expenses
three
months
ended
september
increased
million
million
corresponding
period
primarily
due
increases
external
clinical
development
costs
related
sotagliflozin
subsequent
termination
alliance
sanofi
selling
general
administrative
sg
expenses
selling
general
administrative
expenses
three
months
ended
september
decreased
million
million
corresponding
period
gain
sale
xermelo
gain
million
recognized
three
months
ended
september
sale
xermelo
related
assets
tersera
net
income
net
income
three
months
ended
september
million
per
diluted
share
compared
net
income
million
per
diluted
share
corresponding
period
three
months
ended
september
net
loss
included
compensation
expense
million
million
respectively
cash
investments
september
lexicon
million
cash
investments
compared
million
december
conference
call
webcast
information
lexicon
management
hold
live
conference
call
webcast
today
et
ct
review
financial
operating
results
provide
general
business
update
number
conference
call
canada
international
conference
id
callers
live
webcast
replay
may
accessed
visiting
lexicon
website
http
events
archived
version
webcast
available
website
days
potent
orally
delivered
selective
small
molecule
inhibitor
target
pain
phenotype
discovered
extensively
characterized
alliance
bristol
myers
squibb
preclinical
studies
demonstrated
central
nervous
system
penetration
reduction
pain
behavior
models
neuropathic
pain
without
affecting
opiate
pathways
lexicon
holds
exclusive
research
development
commercialization
rights
additional
compounds
acting
alliance
sotagliflozin
discovered
using
lexicon
unique
approach
gene
science
sotagliflozin
oral
dual
inhibitor
two
proteins
responsible
glucose
regulation
known
types
responsible
glucose
absorption
gastrointestinal
tract
responsible
glucose
reabsorption
kidney
sotagliflozin
approved
european
union
eu
use
adjunct
insulin
therapy
improve
blood
sugar
glycemic
control
adults
type
diabetes
body
mass
index
kg
could
achieve
adequate
glycemic
control
despite
optimal
insulin
therapy
yet
commercially
launched
lexicon
pharmaceuticals
lexicon
biopharmaceutical
company
mission
pioneering
medicines
transform
patients
lives
program
lexicon
scientists
studied
role
function
nearly
genes
identified
protein
targets
significant
therapeutic
potential
range
diseases
precise
targeting
proteins
lexicon
pioneering
discovery
development
innovative
medicines
safely
effectively
treat
disease
lexicon
advanced
one
medicines
market
pipeline
promising
drug
candidates
discovery
clinical
preclinical
development
diabetes
metabolism
neuropathic
pain
indications
additional
information
please
visit
safe
harbor
statement
press
release
contains
statements
including
statements
relating
lexicon
financial
position
outlook
business
clinical
development
therapeutic
commercial
potential
drug
candidates
addition
press
release
also
contains
forward
looking
statements
relating
lexicon
growth
future
operating
results
discovery
development
products
strategic
alliances
intellectual
property
well
matters
historical
facts
information
statements
based
management
current
assumptions
expectations
involve
risks
uncertainties
important
factors
specifically
including
lexicon
ability
meet
capital
requirements
successfully
conduct
preclinical
clinical
development
obtain
necessary
regulatory
approvals
sotagliflozin
potential
drug
candidates
anticipated
timelines
achieve
operational
objectives
obtain
patent
protection
discoveries
establish
strategic
alliances
well
additional
factors
relating
manufacturing
intellectual
property
rights
therapeutic
commercial
value
drug
candidates
risks
uncertainties
factors
may
cause
lexicon
actual
results
materially
different
future
results
expressed
implied
statements
information
identifying
important
factors
contained
risk
factors
lexicon
annual
report
form
year
ended
december
filed
securities
exchange
commission
lexicon
undertakes
obligation
update
revise
statements
whether
result
new
information
future
events
otherwise
lexicon
pharmaceuticals
inc
selected
financial
data
consolidated
statements
operations
data
three
months
ended
september
nine
months
ended
september
thousands
except
per
share
data
unaudited
unaudited
revenues
net
product
revenue
collaborative
agreements
royalties
revenue
total
revenues
operating
expenses
cost
sales
including
intangible
asset
amortization
research
development
including
compensation
respectively
selling
general
administrative
including
compensation
respectively
impairment
loss
buildings
impairment
loss
intangible
asset
total
operating
expenses
operating
income
gain
sale
xermelo
income
loss
operations
loss
debt
extinguishments
net
interest
expense
interest
income
net
net
income
loss
income
taxes
income
tax
benefit
net
income
loss
net
income
loss
per
common
share
basic
net
income
loss
per
common
share
diluted
shares
used
computing
net
income
loss
per
common
share
basic
shares
used
computing
net
income
loss
per
common
share
diluted
consolidated
balance
sheet
data
thousands
unaudited
cash
investments
property
equipment
net
goodwill
intangible
assets
total
assets
current
debt
accumulated
deficit
total
stockholders
equity
inquiries
chas
schultz
executive
director
corporate
communications
investor
relations
lexicon
pharmaceuticals
cschultz
